Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...
Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The ...
We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...
9h
Biotechnology company Atavistik Bio announced Thursday that it has entered into a research collaboration with Pfizer, Inc. (PFE) to ...
The article " Pfizer: 4 Reasons to Buy This Stock " first appeared on MarketBeat.
Pfizer Inc. defeated a lawsuit from Texas Attorney General Ken Paxton that alleged the pharmaceutical giant misrepresented ...
Sangamo Therapeutics Inc. fell as much as 67% in extended trading after Pfizer Inc. ended its partnership to develop a new ...
Sangamo Therapeutics Inc.’s stock sank sharply on the last day of 2025 as Pfizer Inc. handed back the rights to their collaborative gene therapy hemophilia A program. While it was another big loss to ...
Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market open on Tuesday following ...
Sangamo Biosciences ( (SGMO) ) has shared an update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback